Vazyme(SH:688105)2022-04-21 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥975,338,224.30, representing an increase of 80.07% compared to the same period last year[5] - The net profit attributable to shareholders was ¥431,359,400.13, reflecting a growth of 28.18% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥412,503,311.93, up by 25.79% from the previous year[5] - Total operating revenue for Q1 2022 reached ¥975,338,224.30, a significant increase of 80.0% compared to ¥541,639,956.10 in Q1 2021[38] - Net profit for Q1 2022 was ¥431,359,398.28, representing a 28.2% increase from ¥336,514,049.65 in Q1 2021[39] - Basic and diluted earnings per share for Q1 2022 were both ¥1.08, compared to ¥0.93 in Q1 2021[39] Expenses - Research and development expenses totaled ¥71,157,250.07, which is an increase of 86.32% compared to the same period last year[7] - Total operating costs for Q1 2022 were ¥459,987,180.50, up 200.0% from ¥153,038,269.99 in Q1 2021[38] - Research and development expenses for Q1 2022 were ¥71,157,250.07, up 86.4% from ¥38,191,518.13 in Q1 2021[38] - Sales expenses for Q1 2022 amounted to ¥89,918,252.50, an increase of 88.0% compared to ¥47,806,170.60 in Q1 2021[38] - The company reported a significant increase in sales expenses, which reached ¥65,710,671.29 in Q1 2022, compared to ¥26,881,353.05 in Q1 2021, an increase of 144.5%[56] Cash Flow - The cash flow from operating activities showed a net outflow of ¥72,730,459.02, a decrease of 69.29% year-over-year[5] - Cash inflow from operating activities for Q1 2022 was CNY 974,826,717.20, a significant increase from CNY 521,555,553.48 in Q1 2021, representing a growth of approximately 86.9%[44] - Cash outflow from operating activities totaled CNY 902,096,258.18 in Q1 2022, compared to CNY 284,723,116.95 in Q1 2021, indicating a rise of about 216.5%[44] - Net cash flow from operating activities decreased to CNY 72,730,459.02 in Q1 2022 from CNY 236,832,436.53 in Q1 2021, reflecting a decline of approximately 69.3%[44] - The company reported a cash outflow from financing activities of CNY 9,929,413.42 in Q1 2022, indicating a significant cash drain compared to the previous period[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,458,970,212.67, marking an 18.49% increase from the end of the previous year[7] - Total liabilities increased to ¥898,453,471.96 in Q1 2022, up from ¥479,829,915.56 in Q1 2021, reflecting a growth of 87.2%[38] - Total equity attributable to shareholders reached ¥4,560,516,742.64 in Q1 2022, compared to ¥4,127,289,969.06 in Q1 2021, an increase of 10.5%[38] - The total assets reached ¥5,458,970,212.67 in Q1 2022, up from ¥4,607,119,884.54 in Q1 2021, indicating a growth of 18.5%[38] - The total assets of the company increased to CNY 4,723,259,498.58 as of March 31, 2022, compared to CNY 4,369,881,732.97 at the end of 2021, marking an increase of approximately 8.1%[50] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,557, with the top 10 shareholders holding 72.07% of shares[15] - The largest shareholder, Nanjing Nuowei Investment Management Co., Ltd., holds 161,907,305 shares, accounting for 40.48%[15] - The company has a total of 161,907,305 shares pledged, representing 4.01% of the total shares[15] Inventory and Receivables - The company reported a significant increase in accounts receivable by 57.90%, attributed to expanded sales scale and increased revenue[10] - The inventory increased by 72.20%, driven by the company's expansion in operations to meet market demand[10] - Accounts receivable increased to CNY 386,709,326.28 in Q1 2022 from CNY 290,646,656.10 in Q1 2021, representing a rise of approximately 33.0%[50] - Inventory levels rose to CNY 152,751,118.26 in Q1 2022, compared to CNY 125,723,302.93 in Q1 2021, reflecting an increase of about 21.5%[50] Investment Activities - The company established a wholly-owned subsidiary, Nanjing Nuowei Health Technology Co., Ltd., with a registered capital of ¥10 million to focus on synthetic biology raw material R&D and sales[28] - Net cash flow from investing activities was negative CNY 704,516,251.22 in Q1 2022, worsening from negative CNY 253,654,182.38 in Q1 2021[46] - The company's investment activities generated cash inflows of ¥1,179,456,011.83 in Q1 2022, down from ¥1,611,838,987.79 in Q1 2021[58] - Net cash flow from investment activities was -403,401,918.52, compared to -270,835,118.88 in the previous period, indicating a decline in investment performance[60]